ACCESSIBILITY

24/7

Headlines

11:25

From Hyundai offshoot to AI powerhouse: SK Hynix’s unlikely rise

10:56

When a Wiz founder's investment becomes a test of Israel's institutions

10:32

The Bank of Israel's real message wasn't about interest rates

09:58

“The real competitor is the status quo”: Finterest plans to fix what the wealth management market is missing

Buzz

Most popular

Daily

Weekly

Cyera in advanced negotiations to acquire Oasis Security for over $1 billion

Palo Alto Networks and Koi Security sued over alleged AI error in cyber threat report

Defense Ministry joins opposition to Zim's $4.2 billion sale to Hapag-Lloyd

“Everything we built was no longer relevant”: Tom Livne on Verbit’s collapse from a $2 billion valuation

Court halts Patriarchate plan to sell prime Jerusalem land after 25-year delay

More news

Immunotherapy

9 stories about Immunotherapy

Cancer Immunotherapy Startup NeoTX Raises $45 Million

20.02.20|Adi Pick

NeoTX uses STR to bind genetically engineered bacteria to tumor cells and simultaneously activate the antibacterial response of distant immune cells

Allogenic Immunotherapy Company Adicet Bio Raises $80 Million

02.10.19|Meir Orbach

Founded by Israeli chemist Aya Jakobovits, Adicet develops universal immune cell therapies based on gamma delta T cells to treat different forms of cancer

CEO of Nasdaq-Listed Cell Immunotherapy Company Enlivex Steps Down

02.10.19|Tzally Greenberg

Enlivex develops cell-based treatments for life-threatening immune and inflammatory conditions, such as graft versus host disease, a post bone marrow transplant complication

Compugen Falls 17% on Employee Cuts Announcement

27.02.19|Lilach Baumer

The Nasdaq-listed cancer immunotherapy company published its fourth quarter and full year results for 2018 Tuesday

Bristol-Myers Squibb Invests $12 Million in Israeli Immunotherapy Company Compugen

12.10.18|Dror Reich

The investment is part of a clinical trial collaboration for a treatment that combines Compugen’s investigational antibody with an immune checkpoint inhibitor from Bristol-Myers Squibb

AstraZeneca Signs Deal with Cancer Immunotherapy Company Compugen

03.04.18|Lilach Baumer

The deal has the potential to be worth over $200 million for Nasdaq-listed Compugen

Kite Pharma’s Cancer Drug Gets Regulatory Nod

19.10.17|Lilach Baumer

The cancer-treatment company, bought by Gilead Science in August for $11.9 billion, will sell one treatment course of the drug for $373,000

Kite Pharma Sale Triggers Scientist Quarrel

02.10.17|Zohar Shahar Levy

Zelig Eshhar who patented the company’s core technology is now being sued by his former PhD student and current pharma entrepreneur

Cell Immunotherapy Company Raises $8 Million

24.09.17|Lilach Baumer

Enlivex Therapeutics Ltd. is a clinical-stage company specializing in autoimmune and inflammatory conditions